Megacap opportunities outside SMID-cap focus

Conviction: 72% · Horizon: 5Y · 2026-07-14
Eli Lilly’s ~$1T market cap understates its pipeline and platform build-out

A trillion-dollar valuation can still leave room when obesity, diabetes, and neuroscience franchises are scaling with durable pricing power and a deep late-stage pipeline. Revenue and indication expansion can outpace what the current multiple implies.

Instrument Side Target Reason
LLY Long Scale in metabolic and neuroscience therapies plus a broad development slate supports earnings power above what a $1T cap typically prices in for a single-product story.
Micron benefits from memory demand tied to AI infrastructure growth

High-bandwidth memory and DRAM/NAND cycles are tightening as hyperscale and edge AI deployments absorb supply. Margins and capex discipline can amplify upside when bit growth reaccelerates.

Instrument Side Target Reason
MU Long AI-driven memory intensity and improving industry supply-demand balance favor leaders with HBM and advanced node exposure.

Themes

The content on this page is for informational purposes only and does not constitute financial advice. Stoquate is not a licensed financial advisor. Always conduct your own research and consult a qualified professional before making any investment decisions.